Crescent Biopharma/$CBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crescent Biopharma
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Ticker
$CBIO
Sector
Primary listing
Employees
44
Headquarters
Website
CBIO Metrics
BasicAdvanced
$367M
-
-$12.81
-
-
Price and volume
Market cap
$367M
52-week high
$21.40
52-week low
$8.72
Average daily volume
183K
Financial strength
Current ratio
6.561
Quick ratio
6.409
Long term debt to equity
0.596
Total debt to equity
0.81
Interest coverage (TTM)
-69.85%
Profitability
EBITDA (TTM)
-152.548
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,419.61%
Operating margin (TTM)
-1,407.52%
Effective tax rate (TTM)
-1.32%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-69.15%
Return on equity (TTM)
-160.75%
Valuation
Price to revenue (TTM)
12.23
Price to book
1.84
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
-0.918
Free cash flow yield (TTM)
-108.92%
Free cash flow per share (TTM)
-12.025
Growth
Earnings per share change (TTM)
-86.24%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crescent Biopharma stock?
Crescent Biopharma (CBIO) has a market cap of $367M as of March 25, 2026.
What is the P/E ratio for Crescent Biopharma stock?
The price to earnings (P/E) ratio for Crescent Biopharma (CBIO) stock is 0 as of March 25, 2026.
Does Crescent Biopharma stock pay dividends?
No, Crescent Biopharma (CBIO) stock does not pay dividends to its shareholders as of March 25, 2026.
When is the next Crescent Biopharma dividend payment date?
Crescent Biopharma (CBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Crescent Biopharma?
Crescent Biopharma (CBIO) does not currently have a Beta indicator.